A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine
Interventions: DEVICE: Mapisal|OTHER: Urea hand-foot cream
Sponsor: AIO-Studien-gGmbH